PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS.
OBJECTIVE
Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Both functional and nonfunctional adrenal tumors are associated with a higher risk of cardiovascular events and mortality. We aimed to investigate plasma PTX3 levels in patients with functioning and nonfunctioning adrenal tumors and determine its relationship with cardiovascular risk factors.


METHODS
Twenty-one patients with functional adrenal tumors (11 pheochromocytomas, 9 Cushing syndrome, and 1 primary hyperaldosteronism), 28 patients with nonfunctional adrenal incidentalomas, and 40 healthy controls were enrolled in the study. Serum PTX3 levels were measured using a human PTX3 enzyme-linked immunosorbent assay.


RESULTS
PTX3 concentrations were significantly higher in the adrenal tumor group compared with the control group (3,001.64 ± 374.64 pg/mL vs. 1,173.59 ± 168.89 pg/mL; P<.001). PTX3 concentrations were positively correlated with carotid intima media thickness (CIMT) (r2, 0.464; P<.001), high-sensitivity C-reactive protein (hsCRP) (r2, 0.551; P<.001), diastolic blood pressure (r2, 0.334; P = .003), systolic blood pressure (r2, 0.312; P = .006), and urinary metanephrine concentrations (r2, 0.320; P = .041). Serum PTX3 concentrations in patients with functional adrenal tumors and comorbidities including hypertension, diabetes mellitus, or CVD were higher than in those without comorbidities (3,654.54 ± 447 pg/mL vs. 1,026.96 ± 447.97 pg/mL; P = .008).


CONCLUSIONS
We found that serum PTX3 concentrations increased in both functional and nonfunctional adrenal tumors. PTX3 levels were correlated with cardiovascular risk factors such as CIMT, hsCRP, and blood pressure.


BACKGROUND
BMI = body mass index; CIMT = carotid intima-media thickness; CRP = C-reactive protein; CT = computed tomography; CVD = cardiovascular disease; FGF2 = fibroblast growth factor 2; hsCRP = high-sensitivity C-reactive protein; PA = primary hyperaldosteronism; PTX3 = pentraxin 3.
Muhammed
M
Kizilgul
Selvihan
S
Beysel
Ozgur
O
Ozcelik
Seyfullah
S
Kan
Mahmut
M
Apaydin
Mustafa
M
Caliskan
Bekir
B
Ucan
Erkam
E
Sencar
Seyda
S
Ozdemir
Erman
E
Cakal
D000236:Adenoma / Q000453:epidemiology / Q000378:metabolism*; D000310:Adrenal Gland Neoplasms / Q000453:epidemiology / Q000378:metabolism*; D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000378:metabolism; D016022:Case-Control Studies; D003480:Cushing Syndrome / Q000453:epidemiology / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000378:metabolism; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000453:epidemiology / Q000378:metabolism*; D006973:Hypertension / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D008676:Metanephrine / Q000652:urine; D008875:Middle Aged; D010673:Pheochromocytoma / Q000453:epidemiology / Q000378:metabolism*; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D000099153:Pentraxins
D002097:C-Reactive Protein; D008676:Metanephrine; D000683:Serum Amyloid P-Component; D000099153:Pentraxins